Lustro Comments

Discuss this Deal with other Investors


Developing The First Disease Modifying Drug to Regenerate Peripheral Nerves

Claim My Business
Security Type
Technology, Financial Services, Healthcare & Medical, Education, Health & Fitness
Min Investment
San Diego, CA
Expected Close Date
April 29, 2024
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

WinSanTor Inc. is a clinical-stage biotechnology company focused on the discovery and development of treatments for peripheral neuropathies, including diabetic peripheral neuropathy, chemo- and HIV-induced peripheral neuropathy, and others. It recently completed Phase 1 trials for its lead drug, WST-057, and will begin recruiting for its Phase 2 trials in Canada to treat patients with diabetic peripheral neuropathy.

WinSanTor has a drug in FDA trials that shows significant promise in combating neuropathy. Neuropathy causes debilitating loss of feeling, particularly in digits that can impede simple functions and even walking. It’s generally caused by diabetes, chemotherapy, or nervous system disease. 
The disease affects almost 300 people globally. This is a significant global market opportunity without similar competing compounds. The company believes that a 5% US market for peripheral neuropathies alone would make WST-057 (drug under process for FDA approval) one of the top-grossing drugs globally. The drug has been in use in Western countries for 30 years which should be helpful to its approval process. In addition, WinSanTor has transitioned this compound from tablet form to topical. 

The company faces competition for patients with peripheral neuropathy from companies that produce pain drugs, companies that are developing medical devices that treat peripheral neuropathy, and companies that are developing supplements that claim to treat peripheral neuropathy. Against these competitors, the company has strong economic MOAT in the form of the top KOLs, patents & other intellectual property, partners, and strategy.

The product proves validated science rewarded by innovation grants (>$40M) and licensing deals (>$200M + royalty). The company had a revenue of $11.95M in 2022 against $7.24M in 2021. The gross margin was 96.61% in 2022 compared to 85.68% in 2021. Over the period of April-June 2023, the company had an average revenue of $876k/month, COGS of $900/month, and operational expenses of $825.6k /month. The net profit for the same period was $49.6k/month implying that the company is profitable.

Key Deal Facts

FIRST drug regenerating peripheral nerves (humans) - combating direct cause of peripheral neuropathy Repurposed medication w/ UNPARALLELED safety profile in FINAL phase (PH3) of clinical studies (DPN) UNMET need affecting 100s of millions, ignored/neglected by industry, e.g., few, if any, competitors VALIDATED science rewarded by innovation grants (>$40M) and licensing deal (>$200M + royalty) Strong economic MOAT (the top KOLs, patents & other intellectual property, partners and strategy) CEO's past companies were snatched by tech giants Qualcomm and Apple, tech now standards in industry Industry ICONS lead our board, driving disruptive and transformative changes in healthcare LAST crowdfunding investment opportunity before drug approval and IPO (~2-3 years)

Use of Proceeds

The company plans to use the funds for drug manufacturing for clinical trials, toxicity trials to initiate studies in the US, automating review of biological samples, and platform fees.

Management Team / Advisory Board Bios

The management team is very strong.

Stanley Kim, Founder
Stanley has worked with some of the most iconic scientists. Two of the companies he co-founded, Machine Perception Technologies and SoftMax were acquired by Apple and Qualcomm, and technologies are now standards in their industry. He works full-time at the WinSanTor. 

Nigel Calcutt, Co-Founder
Nigel is Prof. of Pathology at UC San Diego. He is also a Lead Preclinical Contractor at NIH NIDDK-RAID and is one of the leading experts in diabetic peripheral neuropathy. This is his first startup. 

Paul Fernyhough, Co-Founder
Paul is a professor in Pharmacology & Therapeutics at the University of Manitoba. He spent 20+ years in diabetic neuropathy and is one of the leading experts in diabetic peripheral neuropathy. This is his first startup. 

Lakshmi P. Kotra, Co-Founder
Laxkshmi is a Director at the Center for Molecular Design and Pre formulation at UHN, with expertise in drug development. This is his first startup. 

Valuation Notes

To date, the company has been financed with $750k in debt, $1.35M in equity, $1.65M in convertibles, and $1.7M in SAFEs. This is the last crowdfunding investment opportunity for the company before drug approval and IPO. Currently, the company is raising SAFE at a $500M post-money valuation cap. The valuation is high even after considering the cost of commercializing the product and pending clinical approvals.

Amount Raised : $192,502
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

A CAFES (Contract and Future Equity Stake) can convert into different types of equity upon a Triggering Event, such as: common or preferred stock for a corporation, limited partnership interest for a limited partnership and membership interest for a limited liability company. At the time of the Triggering Event, the specific rights and limitations associated with the equity stake being issued to the investors will be determined and disclosed by the Entrepreneur.

Research Reports

No reports have been submitted

Become a Reporter